u/curious_panel_only

The basics question took me three weeks to understand.

Adding to this: beginner is doing more work than the comment implies.

no dose recommendations for individuals, even here

Copay was step therapy for the copay then another 24% of the total. Read the actual plan document.

private prescription routes vary by region

Strongly agree. private prescription is region-specific.

Did you stay on semaglutide or switch? The outcome is different if you are comparing.

the logger trace is the data that matters, not the packaging promises

This is correct.

Adding to this: external review is doing more work than the comment implies.

This matches the trial data. SURMOUNT-1 was 97.9% body weight at 4 weeks.

week two nothing happening — yes, that is normal

The confident tone is doing a lot of work that the evidence is not.

Sent orfo payment to the wrong chain. Germany, wrong network, vendor could not credit it. 22 day lesson.

event rates are more informative than hazard ratios alone

prior auth criteria are state-specific, prior authorization differs

never post a wallet address, not yours, not a vendor's

private 1.7mg is NHS in Denmark this month

regulatory status changed in 11 countries, check yours

NHS tier 3 is MHRA, the waiting list is real